文献リスト

1) Rogers j, Mitchell GW. The relation of obesity to menstrual disturbances. N Engl J Med. 1952; 247: 53-6

2) Rich-Edwards JW, Goldman MB, Willett WC, et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol. 1994; 171: 171-7

3) Zaadstra BM, Seidell JC, Van Noord PA, et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. BMJ. 1993; 306: 484-7

4) Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with poly-cystic ovary syndrome. BJOG. 2006; 113: 1148-59

5) Gambineri A, Pelusi C, Vincennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002; 26: 883-96

6) Galtier-Dereure F, Pujol P, Dewailly D, et al. Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum Reprod. 1997; 12 Suppl 1: 88-96

7) Lobo RA, Gysler M, March CM, et al. Clinical and laboratory predictors of clomiphene re-sponse. Fertil Steril. 1982; 37: 168-74

8) Pasquali R, Casimirri F, Plate L, et al. Charac-terization of obese women with reduced sex hor-mone-binding globulin concentrations. Horm Metab Res. 1990; 22: 303-6

9) Kirschner MA, Samojlik E, Drejka M, et al. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab. 1990; 70: 473-9

10) Poretsky L, Cataldo NA, Rosenwaks Z, et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999; 20: 535-82

11) Agarwal A, Gupta S, Sharma RK. Role of oxi-dative stress in female reproduction. Reprod Biol Endocrinol. 2005; 14: 28-49

12) Jensen TK, Scheike T, Keuding N, et al. Fecun-dability in relation to body mass and menstrual cycle patterns. Epidemiology. 1999; 10: 422-8

13) Jensen TK, Andersson AM, Jorgensen N, et al. Body mass index in relation to semen quality and reproductive hormones among 1, 558 Danish men. Fertil Steril. 2004; 82: 863-70

14) Kort Hi, Massey JB, Elsner CW, et al. Impact of body mass index values on sperm quantity and quality. J Androl. 2006; 27: 450-2

15) Hippisley-Cox J, Coupland C, Pringle M, et al. Married couples' risk of same disease: cross sectional study. BMJ. 2002; 325: 636-40

16) Zaadstra BM, Seidell JC, Van Noord PA, et al. Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. BMJ. 1993; 306: 484-7

17) Guzick DS, Wing R, Smith D, et al. Endocrine consequences of weight loss in obese, hyper-androgenic, anovulatory women. Fertil Steril. 1994; 61: 598-604

18) Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod. 1996; 11: 1884-91

19) Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in preg-nancy and ovulation rates in anovulatory obese women. Hum Reprod. 1995; 10: 2705-12

20) Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improve-ment in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998; 13: 1502-5

21) Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hor-mone. J Clin Endocrinol Metab. 1999; 84: 1470-4

22) Moran LJ, Noakes M, Clifton PM, et al Dietary composition in restoring reproductive and meta-bolic physiology in overweight women with poly-cystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88: 812-9

23) Bloomfield FH, Oliver MH, Hawkins P, et al. A periconceptional nutritional origin for nonin-fectious preterm birth. Science. 2003; 300: 606

24) Tsagareli V, Noakes M, Norman RJ. Effect of a very-low-calorie diet on in vitro fertilization outcomes. Fertil Steril. 2006; 86: 227-9

25) Villamor E, Cnattingius S, Villamor E, et al. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet. 2006; 368: 1164-70

26) Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005; 353: 2111-20

27) Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril. 2004; 82: 421-9

28) Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006; 21: 80-9

29) Teitelman M, Grotegut CA, Williams NN, et al. The impact of bariatric surgery on menstrual patterns. Obes Surg. 2006; 16: 1457-63

30) Deitel M, Stone E, Kassam HA, et al. Gyne-cologic-obstetric changes after loss of massive excess weight following bariatric surgery. J Am Coll Nutr. 1988; 7: 147-53

31) Dixon JB, Dixon ME, O'Brien PE. Birth outcomes in obese women after laparoscopic adjustable gastric banding. Obstet Gynecol. 2005; 106: 965-72

32) Legro RS, Myers ER, Barnhart HX, et al. Utility of screening for other causes of infertility in women with “known" polycystic ovary syndrome. Fertil Steril. 2007; 87: 442-4

33) Beck JI, Boothroyd C, Proctor M, et al. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev. 2005: CD002249

34) Hammond MG, Halme JK, Tarbert LM, et al. Factors affecting the pregnancy rate in clomi-phene citrate induction of ovulation. Obstet Gynecol. 1983; 62: 196-202

35) Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenor-rheic infertility. J Clin Endocrinol Metab. 1999; 84: 1617-22

36) Legro RS. Pregnancy considerations in women with polycystic ovary syndrome. Clin Obstet Gynecol. 2007; 50: 295-304

37) Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007; 356: 551-66

38) Siebert TI, Kruger TF, Steyn DW, et al. Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome？ A structured litera-ture review. Fertil Steril. 2006; 86: 1432-7

39) Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006; 332: 1485-90

40) Harborne LR, Sattar N, Norman JE, et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005; 90: 4593-8

41) Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary. Arch Gynecol Obstet. 2004; 270: 205-10

42) Douchi T, Oki, Yamasaki H, et al. Body fat patterning in polycystic ovary syndrome women as a predictor of the response to clomiphene. Acta Obstet Gynecol Scand. 2004; 83: 838-41

43) Mulders AG, Laven JS, Eijkemans MJ, et al. Patient predictors for outcome of gonadotrophin ovulation induction in women with normo-gonadotrophic anovulatory infertility: a meta-analysis. Hum Reprod Update. 2003; 9: 429-49

44) Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89: 318-23

45) Balen AH, Platteau P, Andersen AN, et al. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. BJOG. 2006; 113: 1195-202

46) Fedorcsak P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod. 2004; 19: 2523-8

47) Bellvor J, Busso C, Pellicer A, et al. Obesity and assisted reproductive technology outcomes. Reprod Biomed Online. 2006; 12: 562-8

48) Fedorcsak P, Dale PO, Storeng R, et al. Impact of overweight and underweight on assisted reproduction treatment. Hum Reprod. 2004; 19: 2523-8

49) van Swieten EC, van der Leeuw-Harmsen L, Badings EA, et al. Obesity and Clomiphene Challenge Test as predictors of outcome of in vitro fertilization and intracytoplasmic sperm injection. Gynecol Obstet Invest. 2005; 59: 220-4

50) Nichols J, Crane M, Higdon H, et al. Extremes of body mass index reduce in vitro fertilization pregnancy rates. Fertil Steril. 2003; 79: 645-7

51) Carrell DT, Jones KP, Peterson CM, et al. Body mass index is inversely related to intrafollicular HCG concentrations, embryo quality and IVF outcome. Reprod Biomed Online. 2001; 3: 109-11

52) Maheshwari A, Stofberg L, Bhattacharya S, et al. Effect of overweight and obesity on assisted reproductive technology--a systematic review. Hum Reprod Update. 2007; 13: 433-44

53) Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril. 2006; 85: 1319-40

54) Plymate SR, Matej LA, Jones RE, et al. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988; 67: 460-4

55) Moschos S, Chan JL, Mantzoros CS, et al. Leptin and reproduction: a review. Fertil Steril. 2002; 77: 433-44

56) Caprio M, Isidori AM, Carta AR, et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology. 1999; 140: 4939-47

57) Isidori AM, Caprio M, Strollo F, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999; 84: 3673-80

58) Strain GW, ZUmoff B, Kroam J, et al. Mild Hypogonadotropic hypogonadism in obese men. Metabolism. 1982; 31: 871-5

59) Faldman HA, Goldstain I, Hatzichkristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151: 54-61

60) Bacon CG, Mittloman MA, Kawachi I, et al. A prospective study of risk factors for erectile dysfunction. J Urol. 2006; 176: 217-21

61) Eaposlto K, Giugllano F, Di Palo C, et al. Effect of a mediterranean-style diet on endothelial dys-function and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004; 292: 1440-6

62) Stefan N, Stumvoll M. Adiponectin—its role in metabolism and beyond. Horm Metab Res. 2002; 34: 469-74

63) Arita Y, KiharaS, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adipo-nectin, in obesity. Biochem Biophys Res Commun. 1999; 257: 79-83

64) Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001; 86: 3815-9

65) Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-6

66) Spranger J, Mohlig M, Wegewitz U, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004; 61: 738-46

67) Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003; 88: 1594-602

68) Ryan AS, Nicklas BJ, Berman DM, et al. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord. 2003; 27: 1066-71

69) Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20: 1595-9

70) Deura I, Harada T, Taniguchi F, et al. Reduction of estrogen production by interleukin-6 in a human granulosa tumor cell line may have implications for endometriosis-associated infertility. Fertil Steril. 2005; 83 Suppl 1: 1086-92

71) Amoto G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol. 2003; 101: 1177-82

72) Yoshida S, Harada T, Iwabe T, et al. A com-bination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis. Hum Reprod. 2004; 19: 1821-5

73) Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care. 2004; 27: 1699-705

74) Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004; 12: 962-71

75) Lonnqvist F, Amer P, Nordfors L, et al. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med. 1995; 1: 950-3

76) Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334: 292-5

77) Cervero A, Horcajadas JA, Dominguez F, et al. Leptin system in embryo development and implantation: a protein in search of a function. Reprod Biomed Online. 2005; 10: 217-23

78) Hamm ML, Bhat GK, Thompson WE, et al. Folliculogenesis is impaired and granulosa cell apoptosis is increased in leptin-deficient mice. Biol Reprod. 2004; 71: 66-72

79) Spicer LJ, Francisco CC. Adipose obese gene product, leptin, inhibits bovine ovarian thecal cell steroidogenesis. Biol Reprod. 1998; 58: 207-12

80) Xydakis AM, Case CC, Jpnes PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004; 89: 2697-703

81) Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990; 39: 1044-8

82) Glueck CL, Wang P, Bornovali S, et al. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003; 52: 1627-32

83) Arvidsson E, Viguerie N, Andersson I, et al. Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes. 2004; 53: 1966-71

84) van Dielen FM, Buurman WA, Hadfoune M, et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab. 2004; 89: 4062-8

85) Fain JN, Bahouth SW, Madan AK. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord. 2004; 28: 616-22

86) Bruun JM, Pederson SB, Kristensen K, et al. Opposite regulation of interleukin-8 and tumor necrosis factor-alpha by weight loss. Obes Res. 2002; 10: 499-506

87) Kirchgessner TG, Uysal KT, Wiesbrock SM, et al. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest. 1997; 100: 2777-82

88) Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002; 51: 3176-88

89) Okuda K, Sakumoto R. Multiple roles of TNF super family members in corpus luteum function. Reprod Biol Endocrinol. 2003; 1: 95

90) Wood JR, Strauss JF. Multiple signal transduction pathways regulate ovarian steroidogenesis. Rev Endocr Metab Disord. 2002; 3: 33-46. Review. No abstract available

91) Tabibzadeh, Zupi E, Babaknia A, et al. Site and menstrual cycle-dependent expression of proteins of the tumour necrosis factor (TNF) receptor family, and BCL-2 oncoprotein and phase-specific production of TNF alpha in human endometrium. Hum Reprod. 1995; 10: 277-86

92) Berman J, Girrardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol. 2005; 174: 485-90

93) Puder JJ, Varga S, Kraenzlin M, et al. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab. 2005; 90: 6014-21

94) Zhao Y, Nichols JE, Valdez R, et al. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1. 4. Mol Endocrinol. 1996; 10: 1350-7

95) Bastard JP, Vidal H, Jardel C, et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects. Int J Obes Relat Metab Disord. 2000; 24: 70-4

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp